South Dakota-based Covid-19 transgenic cow antibody startup claims its first PhIII win

Zachary Brennan

Senior Editor

SAB Biotherapeutics, known for collecting and distilling antibodies from cows with humanized immune systems, on Wednesday said a Phase III trial it ran for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

South Dakota-based Covid-19 transgenic cow antibody startup claims its first PhIII win

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

South Dako­ta-based Covid-19 trans­genic cow an­ti­body start­up claims its first PhI­II win

Senior Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

South Dakota-based Covid-19 transgenic cow antibody startup claims its first PhIII win